ID   SK-MM-1
AC   CVCL_A478
SY   SK-MM1; SKMM-1; SKMM1; SK-MY-1; SK-My-1
DR   BTO; BTO:0006521
DR   EFO; EFO_0005457
DR   BioSample; SAMN03470877
DR   cancercelllines; CVCL_A478
DR   Cosmic; 720782
DR   Cosmic; 760399
DR   Cosmic; 2081407
DR   Cosmic; 2302414
DR   Cosmic; 2367273
DR   Cosmic; 2391803
DR   DSMZ; ACC-758
DR   DSMZCellDive; ACC-758
DR   GEO; GSM143343
DR   SKY/M-FISH/CGH; 2544
DR   Wikidata; Q54954407
RX   CelloPub=CLPUB00604;
RX   DOI=10.1007/0-306-46877-8_4;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=2506399;
RX   PubMed=6582512;
RX   PubMed=8943038;
RX   PubMed=10557056;
RX   PubMed=10936422;
RX   PubMed=11157491;
RX   PubMed=11429052;
RX   PubMed=12886255;
RX   PubMed=17171682;
RX   PubMed=17229644;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=25877200;
RX   PubMed=32123307;
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/human-multiple-myeloma-cell-line-sk-mm-1
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 440.
CC   Characteristics: Produces Ig kappa.
CC   Doubling time: 32 hours (PubMed=2506399); ~48 hours (DSMZ=ACC-758).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (PubMed=11157491).
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): DSMZ=ACC-758; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 12
ST   D16S539: 13,14
ST   D18S51: 16,17
ST   D19S433: 13
ST   D21S11: 28,32
ST   D2S1338: 22,26
ST   D3S1358: 14,17
ST   D5S818: 8,11
ST   D7S820: 8,12
ST   D8S1179: 14
ST   FGA: 24
ST   Penta D: 2.2,13 (PubMed=25877200)
ST   Penta D: 3,13 (DSMZ=ACC-758)
ST   Penta E: 10,12
ST   TH01: 7
ST   TPOX: 8,10
ST   vWA: 18
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   55Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 02-05-24; Version: 24
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=2506399;
RA   Eton O., Scheinberg D.A., Houghton A.N.;
RT   "Establishment and characterization of two human myeloma cell lines
RT   secreting kappa light chains.";
RL   Leukemia 3:729-735(1989).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=8943038; DOI=10.1073/pnas.93.24.13931;
RA   Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L.,
RA   Kuehl W.M.;
RT   "Promiscuous translocations into immunoglobulin heavy chain switch
RT   regions in multiple myeloma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996).
//
RX   PubMed=10557056; DOI=10.1038/sj.leu.2401563;
RA   Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A.,
RA   Shimizu S., Taniwaki M., Ueda R.;
RT   "Detection of MUM1/IRF4-IgH fusion in multiple myeloma.";
RL   Leukemia 13:1812-1816(1999).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=11157491; DOI=10.1182/blood.V97.3.729;
RA   Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A.,
RA   Kuehl W.M., Bergsagel P.L.;
RT   "Activated fibroblast growth factor receptor 3 is an oncogene that
RT   contributes to tumor progression in multiple myeloma.";
RL   Blood 97:729-736(2001).
//
RX   PubMed=11429052; DOI=10.1111/j.1349-7006.2001.tb01142.x;
RA   Hanamura I., Iida S., Akano Y., Hayami Y., Kato M., Miura K.,
RA   Harada S., Banno S., Wakita A., Kiyoi H., Naoe T., Shimizu S.,
RA   Sonta S.-i., Nitta M., Taniwaki M., Ueda R.;
RT   "Ectopic expression of MAFB gene in human myeloma cells carrying
RT   (14;20)(q32;q11) chromosomal translocations.";
RL   Jpn. J. Cancer Res. 92:638-644(2001).
//
RX   PubMed=12886255; DOI=10.1038/sj.leu.2403026;
RA   Hayami Y., Iida S., Nakazawa N., Hanamura I., Kato M., Komatsu H.,
RA   Miura I., Dave B.J., Sanger W.G., Lim B., Taniwaki M., Ueda R.;
RT   "Inactivation of the E3/LAPTm5 gene by chromosomal rearrangement and
RT   DNA methylation in human multiple myeloma.";
RL   Leukemia 17:1650-1657(2003).
//
RX   PubMed=17171682; DOI=10.1002/gcc.20404;
RA   Lombardi L., Poretti G., Mattioli M., Fabris S., Agnelli L.,
RA   Bicciato S., Kwee I., Rinaldi A., Ronchetti D., Verdelli D.,
RA   Lambertenghi-Deliliers G., Bertoni F., Neri A.;
RT   "Molecular characterization of human multiple myeloma cell lines by
RT   integrative genomics: insights into the biology of the disease.";
RL   Genes Chromosomes Cancer 46:226-238(2007).
//
RX   PubMed=17229644; DOI=10.3324/haematol.10300;
RA   Sanda T., Iida S., Kayukawa S., Ueda R.;
RT   "Induction of class II major histocompatibility complex expression in
RT   human multiple myeloma cells by retinoid.";
RL   Haematologica 92:115-120(2007).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003;
RA   Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J.,
RA   Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T.,
RA   Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C.,
RA   Brents L.A., Kumar S.K., Greipp P., Dispenzieri A., Bryant B.,
RA   Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M.,
RA   Stewart A.K., Carpten J.D., Bergsagel P.L.;
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//